Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $2.98B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.37M
Average 2.42M
Income Statement
Follow revenue through to earnings.
Revenue
$1.03B
FY 2025 · Annual
+64.0% YoYOperating Income
-$136.50M
FY 2025 · Annual
Net Income
-$296.80M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.83M | 117.01M | 285.14M | 627.24M | 1.03B |
| Cost of Revenue | 0 | 65.36M | 144.21M | 234.58M | 408.1M |
| Gross Profit | 68.83M | 51.64M | 140.93M | 392.66M | 620.8M |
| Gross Margin | 100.0% | 44.1% | 49.4% | 62.6% | 60.3% |
| Research & Development | 313.35M | 335.65M | 382.22M | 413.54M | 414.7M |
| Selling, General & Admin | 149.5M | 174.05M | 200.93M | 284.26M | 341.6M |
| Operating Expenses | 461.11M | 507.26M | 580.41M | 695.9M | 757.3M |
| Depreciation & Amortization | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M |
| EBITDA | (392.38M) | (416.54M) | (477.87M) | (113.16M) | (232.3M) |
| EBITDA Margin | -570.1% | -356.0% | -167.6% | -18.0% | -22.6% |
| Operating Income | (392.29M) | (455.62M) | (439.49M) | (303.24M) | (136.5M) |
| Operating Margin | -570.0% | -389.4% | -154.1% | -48.3% | -13.3% |
| Interest Income | 971K | 8.18M | 54.49M | 61.2M | 40.1M |
| Interest Expense | 900K | 10.8M | 21.79M | 21.62M | 21.4M |
| Other Income / Expenses | (14.91M) | 9.9M | (80.63M) | 145.11M | (146.1M) |
| Income Before Tax | (407.2M) | (445.72M) | (520.12M) | (158.13M) | (282.6M) |
| Pre-Tax Margin | -591.6% | -380.9% | -182.4% | -25.2% | -27.5% |
| Income Tax Expense | (3.61M) | 625K | (1.86M) | 18.89M | 14.2M |
| Net Income | (403.58M) | (446.35M) | (518.25M) | (177.03M) | (296.8M) |
| Net Margin | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% |
| EPS (Basic) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| EPS (Diluted) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| 140.85M | 159.04M | 176.08M | 182.85M | 184.32M | |
| 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
LEGN Earnings Waterfall · TTM
NASDAQ:LEGN · Revenue to Net Income
Key Ratios
Analysis
$1.4B of revenue converted into -$215.0K of net income for the selected period. Gross margin is 56.4% and net margin is -1.2%, showing how much revenue survives after costs and taxes. EPS is $-0.03, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Nov 4, 2026 | |
| 6-K | 6-K filing | Oct 15, 2026 | |
| 6-K | 6-K filing | Oct 13, 2026 |
How much revenue does LEGN generate?
Legend Biotech Corporation (LEGN) reported $1.03B of revenue in fiscal 2025.
Is LEGN profitable?
Legend Biotech Corporation (LEGN) reported -$296.80M of net income, with a net margin of -28.8%.
Continue the stock analysis
Jump to another research area for this company.